**Name:** ADDAX Biosciences Ltd  
**Foundation:** 2017  
**Sector of activity:** Medical Devices  
**Activities:** Our project proposes a revolution in the fixative market by the introduction of a reagent that will allow the optimal tissue fixation at structural and molecular level combined with the absence of toxicity and carcinogenic activity, at variance of the fixative in use, formalin (a solution of formaldehyde). Of notice, in the European Union, the eradication of formaldehyde from workplaces has been mandated, by EU n. 1907/2006 and 1272/2008, starting from August 2017.  
**Products:** ADDAX Biosciences aims to introduce into the market a histological fixative as alternative to formalin, based on an innovative glyoxal solution: Acid Deprived DiAldehyde FiXative, ADDAX.  
**Reference market:** The addressable market is represented by the healthcare segment, in particular hospitals, research centres and private laboratories hosting pathology services. The annual usage of formalin can be estimated in more than 1 million liters in Italy  
**Reference University:** University of Torino  

**Contacts:**  
Addax Biosciences s.r.l.  
C.so Vittorio Emanuele II, 12  
info@addaxbio.com  
www.addaxbio.com